Emmaus Life Sciences Inc - Company Profile
Powered by 
All the data and insights you need on Emmaus Life Sciences Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Emmaus Life Sciences Inc Strategy Report
- Understand Emmaus Life Sciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Emmaus Life Sciences Inc (Emmaus) is a commercial-stage biopharmaceutical company. It is involved in the discovery, development, marketing and sale of innovative treatments and therapies, primarily for rare and orphan diseases and is primarily focusing on its product development efforts in Sickle Cell Disease, a genetic disorder. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has established several collaborative relationships for commercialization and distribution of its product to selected pharmacies and hospitals. Emmaus is headquartered in Torrance, California, the US.
Headquarters
United States of America
Address
21250 Hawthorne Boulevard, Suite 800, Torrance, California, 90503
Website
www.emmausmedical.com
Telephone
1 310 2140065
No of Employees
55
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
EMMA (OTC)
Revenue (2021)
$18.4M
-10.8%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
33.4%
(2021 vs 2020)
Market Cap*
$5.4M
Net Profit Margin (2021)
XYZ
25.3%
(2021 vs 2020)
* As of and is in US$
Emmaus Life Sciences Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Endari |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Financing Agreements | In May, the company invested US$2.001 million in CellSeed Inc. |
| 2022 | Regulatory Approval | In December, the company received regulatory approval for the marketing of Endari from Kuwaiti Marketing Authorization. |
| 2022 | Regulatory Approval | In November, the company received regulatory approval for the marketing of Endari from Qatar Ministry of Public Health. |
Competitor Comparison
| Key Parameters | Emmaus Life Sciences Inc | Teladoc Health Inc | American Well Corp | Avadim Health Inc | Aruvant Sciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Torrance | Purchase | Boston | Asheville | Millburn |
| State/Province | California | New York | Massachusetts | North Carolina | New Jersey |
| No. of Employees | 55 | 5,600 | 1,104 | 226 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Willis Lee | Co-President- Interim; Vice Chairman; Chief Operating Officer | Executive Board | - | - |
| Yasushi Nagasaki | Chief Financial Officer | Senior Management | 2020 | 55 |
| George Sekulich | Senior Vice President - Commercialization; Co-President- Interim; Chief Information Officer | Senior Management | - | - |
| Dale E. Short | Legal Consultant; Secretary | Senior Management | 2018 | - |
| Charles W. Stark | Senior Vice President - Medical Affairs, Clinical and Regulatory | Senior Management | 2013 | 67 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer